4//SEC Filing
PRENDERGAST FRANKLYN G 4
Accession 0001209191-23-052048
CIK 0001472012other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 5:28 PM ET
Size
7.3 KB
Accession
0001209191-23-052048
Insider Transaction Report
Form 4
Immunome Inc.IMNM
PRENDERGAST FRANKLYN G
Director
Transactions
- Award
Common Stock
2023-10-02+60,840→ 60,840 total - Award
Stock Option (Right to Buy)
2023-10-02$1.35/sh+137,725$185,929→ 137,725 totalExercise: $1.35Exp: 2032-09-26→ Common Stock (137,725 underlying)
Footnotes (2)
- [F1]In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
- [F2]In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.
Documents
Issuer
Immunome Inc.
CIK 0001472012
Entity typeother
Related Parties
1- filerCIK 0001233256
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 5:28 PM ET
- Size
- 7.3 KB